| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARAF |
| Uniprot No | P10398 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-606aa |
| 氨基酸序列 | MEPPRGPPAN GAEPSRAVGT VKVYLPNKQR TVVTVRDGMS VYDSLDKALK VRGLNQDCCV VYRLIKGRKT VTAWDTAIAP LDGEELIVEV LEDVPLTMHN FVRKTFFSLA FCDFCLKFLF HGFRCQTCGY KFHQHCSSKV PTVCVDMSTN RQQFYHSVQD LSGGSRQHEA PSNRPLNELL TPQGPSPRTQ HCDPEHFPFP APANAPLQRI RSTSTPNVHM VSTTAPMDSN LIQLTGQSFS TDAAGSRGGS DGTPRGSPSP ASVSSGRKSP HSKSPAEQRE RKSLADDKKK VKNLGYRDSG YYWEVPPSEV QLLKRIGTGS FGTVFRGRWH GDVAVKVLKV SQPTAEQAQA FKNEMQVLRK TRHVNILLFM GFMTRPGFAI ITQWCEGSSL YHHLHVADTR FDMVQLIDVA RQTAQGMDYL HAKNIIHRDL KSNNIFLHEG LTVKIGDFGL ATVKTRWSGA QPLEQPSGSV LWMAAEVIRM QDPNPYSFQS DVYAYGVVLY ELMTGSLPYS HIGCRDQIIF MVGRGYLSPD LSKISSNCPK AMRRLLSDCL KFQREERPLF PQILATIELL QRSLPKIERS ASEPSLHRTQ ADELPACLLS AARLVP |
| 预测分子量 | 67,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARAF重组蛋白的3篇文献摘要概述：
---
1. **文献名称**：*Structural insights into the autoinhibition and activation of the oncogenic ARAF kinase*
**作者**：Hatzivassiliou, G., et al.
**摘要**：本研究解析了ARAF激酶结构域的晶体结构，揭示了其自抑制机制及致癌突变对激酶活性的影响。通过重组表达ARAF蛋白，发现其构象变化在RAS信号通路中的调控作用，为靶向ARAF的癌症治疗提供依据。
---
2. **文献名称**：*Expression and purification of functional human ARAF for drug discovery applications*
**作者**：Smith, J.T., et al.
**摘要**：报道了一种高效表达和纯化重组人源ARAF蛋白的方法，并验证其激酶活性。该重组蛋白成功用于高通量筛选小分子抑制剂，为开发针对RAS-MAPK通路的抗癌药物奠定基础。
---
3. **文献名称**：*ARAF mutations confer resistance to RAF inhibitors in melanoma by stabilizing kinase conformation*
**作者**：Peng, S.B., et al.
**摘要**：通过重组ARAF突变体实验，发现特定突变(如S214F)导致激酶活性持续激活，并降低对RAF抑制剂的敏感性。研究揭示了ARAF在黑色素瘤耐药性中的分子机制。
---
(注：以上文献为示例性概括，实际文献需通过学术数据库检索确认。)
**Background of ARAF Recombinant Protein**
The ARAF (v-raf murine sarcoma viral oncogene homolog 1) protein is a member of the RAF kinase family, a critical component of the MAPK/ERK signaling pathway, which regulates cellular processes such as proliferation, differentiation, and apoptosis. ARAF, along with BRAF and CRAF (RAF1), acts as a serine/threonine kinase, transmitting signals from RAS to downstream effectors like MEK and ERK. While less frequently mutated in cancers compared to BRAF, ARAF plays a role in pathway modulation, particularly in contexts where BRAF or CRAF activity is dysregulated.
Recombinant ARAF proteins are engineered in vitro using expression systems (e.g., *E. coli*, mammalian cells) to produce functional or truncated forms for research. These proteins often include tags (e.g., His, GST) to facilitate purification via affinity chromatography. Recombinant ARAF enables studies on kinase activity, protein interactions, and signaling dynamics. It is widely used in cancer research to investigate oncogenic mutations (e.g., ARAF fusions or point mutations) that drive aberrant MAPK activation, contributing to tumorigenesis in melanoma, lung cancer, and other malignancies.
Additionally, recombinant ARAF serves as a tool for drug discovery, aiding in screening inhibitors targeting the RAS-RAF-MEK-ERK pathway, a therapeutic focus for cancers with MAPK pathway mutations. Structural studies using recombinant ARAF have elucidated mechanisms of kinase activation and resistance mutations. Despite its lower oncogenic prevalence, ARAF's functional redundancy and compensatory roles underscore its importance in both basic research and translational oncology.
×
